Monoclonal antibodies currently in Phase II and III trials for multiple myeloma.Donato F et al. Expert Opin Biol Ther. 2014 Apr 21. [Epub ahead of print].Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide.Yee AJ et al. Br J Haematol. 2014 Apr 25. doi:…
DetailsJumping translocations and high-risk myeloma. Morgan GJ et al. Blood. 2014 Apr 17;123(16):2442-3. doi: 10.1182/blood-2014-02-555755. NF-Kappa B Modulation Is Involved in Celastrol Induced Human Multiple Myeloma Cell Apoptosis. Ni H et al. PLoS One. 2014 Apr 22;9(4):e95846. doi: 10.1371/journal.pone.0095846. eCollection 2014. Next-generation sequencing of peripheral B-lineage cells pinpoints the circulating clonotypic cell pool in multiple…
DetailsAdvances in supportive care for multiple myeloma.Raje NS et al. J Natl Compr Canc Netw. 2014 Apr 1;12(4):502-11.Surgical management of primary tumors of the cervical spine: surgical considerations and avoidance of complications.Kaloostian PE et al. Neurol Res. 2014 Apr 10:1743132814Y0000000367. [Epub ahead of print].Post-operative Cement Augmentation after 360-degree Fusion for Highly Unstable Vertebral Fractures in…
DetailsOsteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results. Jackson GH et al. Br J Haematol. 2014 Mar 27. doi: 10.1111/bjh.12861. [Epub ahead of print]. Carfilzomib-related acute kidney injury may be prevented by N-acetyl-L-cysteine. Wanchoo R et al. J Oncol Pharm Pract. 2014…
DetailsBortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy.Mateos MV et al. Haematologica. 2014 Apr 24. [Epub ahead of print].Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study.Ahn SY et…
DetailsCD14+ CD16+ monocytes rather than CD14+ CD51/61+ monocytes are a potential cytological marker of circulating osteoclast precursors in multiple myeloma. A preliminary study. Petitprez V et al. Int J Lab Hematol. 2014 Mar 24. doi: 10.1111/ijlh.12216. [Epub ahead of print]. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Martinez-Lopez…
DetailsAutophagy in Plasma Cell Pathophysiology. Oliva L et al. Front Immunol. 2014 Mar 12;5:103. eCollection 2014. Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin. Olsen OE et al. Blood Cancer J. 2014 Mar 21;4:e196. doi: 10.1038/bcj.2014.16. Phenotypic, Genomic and Functional Characterization Reveals No Differences between CD138++…
DetailsSurvival of Multiple Myeloma Patients Aged 65-70 Years in the Era of Novel Agents and Autologous Stem Cell Transplantation. A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma and the European Myeloma Network. Ozaki S et al. Acta Haematol. 2014 Mar 22;132(2):211-219. [Epub ahead of print]. Pathways for blood and bowel cancer patients…
DetailsA phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma. Korde N et al. Haematologica. 2014 Mar 21. [Epub ahead of print]. Sotatercept in patients with osteolytic lesions of multiple myeloma. Abdulkadyrov KM et al. Br J Haematol. 2014 Mar 21. doi: 10.1111/bjh.12835. [Epub ahead of print]. Evolution of carfilzomib dose and…
DetailsPharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation.
Nooka AK et al. Biol Blood Marrow Transplant. 2014 Mar 6. pii: S1083-8791(14)00148-7. doi: 10.1016/j.bbmt.2014.02.025. [Epub ahead of print].
Plasma Exchange for Kidney Disease: What Is the Best Evidence?
Hildebrand AM et al. Adv Chronic Kidney Dis. 2014 Mar;21(2):217-227. doi: 10.1053/j.ackd.2014.01.008.